EC5026
EC-5026 inhibitor of Epoxide hydrolase developed by EicOsis as investigational new drug (IND) candidate for the management of neuropathic and inflammatory chronic pain and finished phase Ia clinical trial. Related to TPPU
General
Type : Urea derivative,Trifluoro,Piperidine
Chemical_Nomenclature : 1-[3-fluoro-4-(trifluoromethoxy)phenyl]-3-[1-[(2S)-2-methylbutanoyl]piperidin-4-yl]urea
Canonical SMILES : CCC(C)C(=O)N1CCC(CC1)NC(=O)NC2=CC(=C(C=C2)OC(F)(F)F)F
InChI : InChI=1S\/C18H23F4N3O3\/c1-3-11(2)16(26)25-8-6-12(7-9-25)23-17(27)24-13-4-5-15(14(19)10-13)28-18(20,21)22\/h4-5,10-12H,3,6-9H2,1-2H3,(H2,23,24,27)\/t11-\/m0\/s1
InChIKey : LHRXHTKENPCGSZ-NSHDSACASA-N
Other name(s) : EC-5026,Q66977824,(S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea
MW : 405.4
Formula : C18H23F4N3O3
CAS_number : 1809885-32-2
PubChem : 91933845
UniChem : LHRXHTKENPCGSZ-NSHDSACASA-N
IUPHAR :
Wikipedia :
Target
References (5)
| Title : Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase - Kelly_2024_Proc.Natl.Acad.Sci.U.S.A_121_e2314085121 |
| Author(s) : Kelly AG , Wang W , Rothenberger E , Yang J , Gilligan MM , Kipper FC , Attaya A , Gartung A , Hwang SH , Gillespie MJ , Bayer RL , Quinlivan KM , Torres KL , Huang S , Mitsiades N , Yang H , Hammock BD , Panigrahy D |
| Ref : Proc Natl Acad Sci U S A , 121 :e2314085121 , 2024 |
| Abstract : Kelly_2024_Proc.Natl.Acad.Sci.U.S.A_121_e2314085121 |
| ESTHER : Kelly_2024_Proc.Natl.Acad.Sci.U.S.A_121_e2314085121 |
| PubMedSearch : Kelly_2024_Proc.Natl.Acad.Sci.U.S.A_121_e2314085121 |
| PubMedID: 38330013 |
| Title : Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry - Dey_2024_J.Pharm.Biomed.Anal_244_116116 |
| Author(s) : Dey S , Biradar R , Mane SS , Kunnath Shaji A , Das AP , Agarwal SM , Dengale SJ |
| Ref : J Pharm Biomed Anal , 244 :116116 , 2024 |
| Abstract : Dey_2024_J.Pharm.Biomed.Anal_244_116116 |
| ESTHER : Dey_2024_J.Pharm.Biomed.Anal_244_116116 |
| PubMedSearch : Dey_2024_J.Pharm.Biomed.Anal_244_116116 |
| PubMedID: 38537542 |
| Title : How Robust Is the Ligand Binding Transition State? - Bose_2023_J.Am.Chem.Soc__ |
| Author(s) : Bose S , Lotz SD , Deb I , Shuck M , Lee KSS , Dickson A |
| Ref : Journal of the American Chemical Society , : , 2023 |
| Abstract : Bose_2023_J.Am.Chem.Soc__ |
| ESTHER : Bose_2023_J.Am.Chem.Soc__ |
| PubMedSearch : Bose_2023_J.Am.Chem.Soc__ |
| PubMedID: 37943667 |
| Gene_locus related to this paper: human-EPHX2 |
| Title : Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain - Du_2022_Acta.Pharm.Sin.B_12_1377 |
| Author(s) : Du F , Cao R , Chen L , Sun J , Shi Y , Fu Y , Hammock BD , Zheng Z , Liu Z , Chen G |
| Ref : Acta Pharm Sin B , 12 :1377 , 2022 |
| Abstract : Du_2022_Acta.Pharm.Sin.B_12_1377 |
| ESTHER : Du_2022_Acta.Pharm.Sin.B_12_1377 |
| PubMedSearch : Du_2022_Acta.Pharm.Sin.B_12_1377 |
| PubMedID: 35530144 |
| Title : Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative - Hammock_2021_J.Med.Chem__ |
| Author(s) : Hammock BD , McReynolds CB , Wagner K , Buckpitt A , Cortes-Puch I , Croston G , Lee KSS , Yang J , Schmidt WK , Hwang SH |
| Ref : Journal of Medicinal Chemistry , : , 2021 |
| Abstract : Hammock_2021_J.Med.Chem__ |
| ESTHER : Hammock_2021_J.Med.Chem__ |
| PubMedSearch : Hammock_2021_J.Med.Chem__ |
| PubMedID: 33550801 |